T-BOOSTER CLINICAL TRIAL
T-BOOSTER Trial at BSMMU
We're excited to announce that T-BOOSTER has been accepted for a clinical trial at Bangabandhu Sheikh Mujib Medical University (BSMMU) in Bangladesh. This involves comprehensive trials on 240 participants at a prestigious medical institution, underscores T-BOOSTER's potential and paves the way for rigorous scientific validation. Our team is dedicated to upholding the highest research and ethical standards, aiming to prove T-BOOSTER's effectiveness and safety. This trial is a critical leap towards transforming health and wellness with T-BOOSTER.
For T-BOOSTER, making claims isn't enough; they must be backed by solid evidence. T-BOOSTER isn't just "another supplement"; it's a pioneering force. Every compound in T-BOOSTER is clinically endorsed to counteract thymic shrinkage and enhance immunity. Our journey has been marked by exhaustive clinical exploration:
Format: Randomized, double-blind, placebo-controlled
Participants: 240 healthy adults (aged 18 years and above)
Duration: 4 months.
Comparison: T-BOOSTER vs. placebo.
Key Metrics: Surge in T cell counts and thymic mass growth
Location: Bangabandhu Sheikh Mujib Medical University (BSMMU)
Clinical Validation Strategy
To quantify T-cell receptor excision circles (TRECs) as a marker of thymic output in blood samples of participants at baseline, 2 months and 4 months by DNA analysis.
To compare change in TREC levels between placebo and T-BOOSTER groups over the study duration.
To assess complete blood counts including lymphocyte subsets between groups at baseline, 2 months and 4 months.
To correlate immune outcomes with participant-reported measures of infection frequency, energy, and quality of life.